Compare Illumina, Inc. (ILMN) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Visa Inc — how do they compare? Illumina, Inc. trades at $182.09 (market cap $27.94B), while Visa Inc trades at $359.17 (market cap $685.71B). The key difference: Visa Inc is far larger — about 24.5× Illumina, Inc.'s market cap, and Visa Inc pays a 0.74% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | V | |
|---|---|---|
Market Cap | $27.94B | $685.71B |
Sector | Health | Financials |
52-Week High | $194.33 | $365.14 |
52-Week Low | $91.00 | $295.52 |
Enterprise Value | $29.33B | $696.30B |
Volume | — | 10,431,336 |
Dividend Yield | — | 0.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
Visa (V) trades at $358.56, down 1.8% on the day, but maintains strong technical momentum with bullish moving averages and key support at $357. The company continues to deliver impressive financial performance with Q1 2026 EPS beating expectations at $3.31 versus $3.10, maintaining high profitability margins above 50%. Recent developments include the launch of Intelligent Commerce Connect for AI-powered commerce and expanded stablecoin partnerships.
With 85% analyst buy ratings and a $396.70 consensus price target suggesting 11% upside, Visa presents a compelling long-term investment opportunity. However, investors should monitor rising fintech competition and regulatory pressures that could impact the payment processing landscape. The company's consistent earnings beats and strong cash flow generation support continued dividend growth and shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
